Literature DB >> 17310502

CEACAM1/VEGF cross-talk during neuroblastic tumour differentiation.

P L Poliani1, S Mitola2, M Ravanini1, G Ferrari-Toninelli3, C D'Ippolito4, L D Notarangelo4, L Bercich1, C Wagener5, M Memo3, M Presta2, F Facchetti1.   

Abstract

The role of angiogenesis in tumour progression is a major subject in modern oncology and a correlation between angiogenesis and poor outcome has been demonstrated for human neuroblastomas. However, the role of angiogenesis in the maturation phase of neuroblastic tumours has never been considered. Human carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a potent pro-angiogenic factor and mediator of vascular endothelial growth factor (VEGF)-induced angiogenesis, plays a crucial role during the activation phase of angiogenesis and it has been shown to be expressed in the microvessels of the developing central nervous system as well as in newly formed immature blood vessels in many different tumours and under physiological conditions. The present study has investigated the role of CEACAM1/VEGF-mediated angiogenesis across the whole spectrum of neuroblastic tumours, from undifferentiated to fully differentiated mature ganglioneuromas. CEACAM1 is peculiarly expressed in the microvessels of areas of active tumour maturation among differentiating neuroblastic/ganglion cells, whereas it is completely absent in the vessels of poorly differentiated/undifferentiated as well as in entirely mature Schwannian-rich areas. Interestingly, VEGF expression has been found in differentiating neuroblastic/ganglion cells adjacent to CEACAM1-positive microvessels. In keeping with these observations, VEGF expression was found in human neuroblastoma SH-SY5Y cells during differentiation after retinoic acid treatment. Moreover, conditioned medium from SH-SY5Y cells collected at different stages of differentiation induced progressive in vitro up-regulation of CEACAM1 expression in human umbilical vein endothelial cells (HUVECs) that was abrogated by the specific VEGF receptor-2/KDR inhibitor SU5416. Taken together, these data point to a role for CEACAM1/VEGF cross-talk during the maturation phase of neuroblastic tumours. This may mimic physiological events leading to maturation of the vasculature in the developing normal central nervous system. On the other hand, in poorly differentiated/undifferentiated lesions, VEGF-sustained angiogenesis does not reproduce physiological steps, but rather is associated with tumour aggressiveness and may involve other molecular pathways. Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17310502     DOI: 10.1002/path.2135

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  4 in total

1.  MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.

Authors:  Konstantinos Zormpas-Petridis; Neil P Jerome; Matthew D Blackledge; Fernando Carceller; Evon Poon; Matthew Clarke; Ciara M McErlean; Giuseppe Barone; Alexander Koers; Sucheta J Vaidya; Lynley V Marshall; Andrew D J Pearson; Lucas Moreno; John Anderson; Neil Sebire; Kieran McHugh; Dow-Mu Koh; Yinyin Yuan; Louis Chesler; Simon P Robinson; Yann Jamin
Journal:  Cancer Res       Date:  2019-03-15       Impact factor: 12.701

2.  Human pregnancy specific beta-1-glycoprotein 1 (PSG1) has a potential role in placental vascular morphogenesis.

Authors:  Cam T Ha; Julie A Wu; Ster Irmak; Felipe A Lisboa; Anne M Dizon; James W Warren; Suleyman Ergun; Gabriela S Dveksler
Journal:  Biol Reprod       Date:  2010-03-24       Impact factor: 4.285

3.  Calreticulin Regulates VEGF-A in Neuroblastoma Cells.

Authors:  Wen-Chin Weng; Kuan-Hung Lin; Pei-Yi Wu; Yi-Chien Lu; Yi-Cheng Weng; Bo-Jeng Wang; Yung-Feng Liao; Wen-Ming Hsu; Wang-Tso Lee; Hsinyu Lee
Journal:  Mol Neurobiol       Date:  2014-10-07       Impact factor: 5.590

4.  VEGF expression correlates with neuronal differentiation and predicts a favorable prognosis in patients with neuroblastoma.

Authors:  Wen-Chin Weng; Kuan-Hung Lin; Pei-Yi Wu; Ya-Hsuan Ho; Yen-Lin Liu; Bo-Jeng Wang; Chien-Chin Chen; Yueh-Chien Lin; Yung-Feng Liao; Wang-Tso Lee; Wen-Ming Hsu; Hsinyu Lee
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.